[1] 阮佼,张家骏,曹志刚.重视肠道衰竭在重症急性胰腺炎发病中的作用[J].中国急救医学,2015,35(s2):5-6.[2] 磨庆福.重症急性胰腺炎的发病原因及发病机制研究进展[J].胃肠病学和肝病学杂志,2014,23(9):1107-1110.[3] 赵宁.重症急性胰腺炎诊治进展[J].中华急诊医学杂志,2014, 23(10):67-68.[4] 龙靓,刘湘,郭小兰,等.2012-2014年我院急性胰腺炎患者营养药物使用情况调查[J].药物流行病学杂志,2015(12):740-743.[5] 刘大晟,罗羽宏,李接兴.重症急性胰腺炎早期手术与延期手术治疗效果Meta分析[J].肝胆胰外科杂志,2014,26(4):289-292.[6] 张芬,杨柳,王浩,等.急性胰腺炎的研究进展[J].现代生物医学进展,2016,16(15):2983-2986.[7] Tang Y, Gan X, Cheheltani R, et al. Targeted delivery of vascular endothelial growth factor improves stem cell therapy in a rat myocardial infarction model. Nanomedicine. 2014; 10(8):1711-1718. [8] Atashi F, Modarressi A, Pepper MS. The role of reactive oxygen species in mesenchymal stem cell adipogenic and osteogenic differentiation: a review. Stem Cells Dev. 2015; 24(10):1150-1163. [9] Jeong H, Yim HW, Cho Y, et al. Efficacy and safety of stem cell therapies for patients with stroke: a systematic review and single arm meta-analysis. Int J Stem Cells. 2014;7(2):63. [10] Bruin JE, Saber N, Braun N, et al. Treating diet-induced diabetes and obesity with human embryonic stem cell-derived pancreatic progenitor cells and antidiabetic drugs. Stem Cell Rep. 2015;4(4):605-620. [11] Morigi M, Coppi PD. Cell therapy for kidney injury: different options and mechanisms-mesenchymal and amniotic fluid stem cells. Nephronexp Nephrol. 2014;126(2):59. [12] Teng M, Sun J, Zhao Z, et al. A brief review: adipose-derived stem cells and their therapeutic potential in cardiovascular diseases. Stem Cell Res Ther. 2017;8(1):124. [13] Tabatabaei RQ, Sheykhhasan M. Adipose-derived stromal cell in regenerative medicine: a review. World J Stem Cell. 2017;9(8):107. [14] Saidi RF, Rajeshkumar B, Shariftabrizi A, et al. Human adipose-derived mesenchymal stem cells attenuate liver ischemia-reperfusion injury and promote liver regeneration. Surgery. 2014;156(5):1225-1231. [15] Chen L, Qin F, Ge M, et al. Application of adipose-derived stem cells in heart disease. J Cardiovasc Transl. 2014; 7(7):651-663. [16] 庄培涛,谭雪莹,邱建涛,等.人脂肪间充质干细胞对急性坏死性胰腺炎大鼠治疗疗效的观察[J].中华胰腺病杂志,2017,17(2): 82-87.[17] 竹林,赵健蕾,彭小航,等.大黄中游离蒽醌类化合物在实验性急性胰腺炎大鼠的组织药理学研究[J].中国中药杂志,2014,39(2): 304-308.[18] 刘媛琪,王璐璐,陈立,等.大黄游离蒽醌对重症急性胰腺炎大鼠肝脏的影响[J].时珍国医国药,2015,26(8):1827-1829.[19] Tohill M, Terenghi G. Stem-cell plasticity and therapy for injuries of the peripheral nervous system. Biotechnol Appl Biochem. 2011;40(1):17-24. [20] 陈立,范玲,谭小勇,等.大黄游离蒽醌对重症急性胰腺炎大鼠肠道免疫功能的影响及其作用机制[J].山东医药,2016,56(24):13-16.[21] 刘京伟,陈玲玲,赵安成.血清SAA、CRP、PCT及TAP联合检测在急性重症胰腺炎早期诊治中的临床意义[J].国际检验医学杂志, 2016,37(13):1811-1813.[22] 范永熙,单海滨,李兆然.急性胰腺炎患者血清PCT、IL-6和hs-CRP水平变化的临床意义[J].中国现代医学杂志,2014, 24(10):46-49.[23] 于宁,王晓倩,张欣.IL-10、TGF-β及其mRNA在急性胰腺炎合并肝、肾损伤中的表达[J].检验医学与临床,2017,14(17): 2610-2612.[24] Zhang J, Ning X, Cui W, et al. Transforming growth factor (TGF)-β-induced microRNA-216a promotes acute pancreatitis via Akt and TGF-β pathway in mice. Digest Dis Sci. 2015;60(1):127-35. [25] Akbarshahi H, Sam A, Chen C, et al. Early activation of pulmonary TGF-β1/Smad2 signaling in mice with acute pancreatitis-associated acute lung injury. Mediators Inflamm. 2014;2014(1):148029. [26] Sakao M, Okazaki K, Uchida K, et al. The role of Smad2/3 linker phosphorylation in the regenerative phase of acute pancreatitis. Pancreatology. 2016;16(4):S84-S85. [27] 杨芳勇,王丽娜,岳小强,等.中药大黄在急性胰腺炎治疗中的临床应用[J].中华胰腺病杂志,2015,15(3):212-214.[28] 王璐璐,刘媛琪,陈立,等.大黄游离蒽醌对重症急性胰腺炎大鼠肾损伤的影响[J].中药药理与临床,2015,31(2):31-34.[29] 杨永茂,王平,张艳,等.大黄游离蒽醌在正常和重症急性胰腺炎犬体内吸收动力学比较研究[J].中国中西医结合杂志,2012,32(4): 494-498.[30] 金佳佳,陈建华,杨伟刚.经皮芒硝超声导入对急性胰腺炎患者炎性因子的影响[J].湖北中医杂志,2018,40(1):6-8.[31] 彭智,邱彬.基因重组干扰素γ对呼吸道合胞病毒毛细支气管炎患儿血清SP-D、TGF-β以及IL-4水平的影响[J].中国医师杂志, 2018,20(4):612-614.[32] 许希燕,王巧稚,罗茂,等.阿魏酸联合脂肪间充质干细胞调节TGF-β/Smad信号转导通路对肝星状细胞凋亡的影响研究[J].重庆医学,2018,47(15):1997-2000.[33] 范惠.中医药干预肾纤维化TGF-β1/Smad信号转导通路的体外研究概况[J].泸州医学院学报,2017,40(2):221-224.[34] 孙红,李凤飞,孙子林.转化生长因子β1在胰腺星状细胞致胰腺纤维化中作用研究进展[J].中国医学前沿杂志(电子版),2012,4(5): 51-53.[35] 石占利,方堃,孙静,等.大黄素对重症急性胰腺炎大鼠胰腺细胞凋亡的干预作用[J].中华全科医学,2017,15(11):1830-1834. |